Clinical Trial Update: LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of crizotinib in patients with c-MET or RON-positive metastatic urothelial cancer has been terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ureteral Neoplasms
• Urethral Neoplasms
• Urinary Bladder Neoplasms

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Urinary Bladder Neoplasms, Ureteral Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2021-06-09